Psoriasis and alcohol

Código QR

Psoriasis and alcohol

Caroline Svanström,1,2 Sol-Britt Lonne-Rahm,1 Klas Nordlind21Department of Dermatology, Mälarsjukhuset, Eskilstuna, Sweden; 2Department of Medicine, Solna, Dermatology and Venereology Unit, Karolinska Institutet, Stockholm, SwedenCorrespondence: Caroline SvanströmDepartmen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Svanström C, Lonne-Rahm SB, Nordlind K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	psoriasis alcohol pruritus neurotransmitters Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/668f046e7ad444a88526681539f34b43
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Integrating lifestyle-focused approaches into psoriasis care: improving patient outcomes?
por: Landriscina A, et al.
Publicado: (2016)

Pustular psoriasis: pathophysiology and current treatment perspectives
por: Benjegerdes KE, et al.
Publicado: (2016)

Dermoscopic hemorrhagic dots: an early predictor of response of psoriasis to biologic agents
por: Aimilios Lallas, et al.
Publicado: (2016)

Updates on the Treatment of Erythrodermic Psoriasis
por: Lo Y, et al.
Publicado: (2021)

Psoriasis and uveitis: links and risks
por: Fotiadou C, et al.
Publicado: (2019)

Management of scalp psoriasis: current perspectives
por: Blakely K, et al.
Publicado: (2016)

The Itch-Scratch Cycle: A Review of the Mechanisms
por: Giulia Rinaldi
Publicado: (2019)

Characterization of Cowhage-induced Pruritus in Sensitive Skin: An Observational Laboratory Study
por: Ying Zuo, et al.
Publicado: (2021)

Psoriasis: Targets and Therapy
Publicado: (2012)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado Á, et al.
Publicado: (2018)

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison
por: Hampton P, et al.
Publicado: (2021)

Risankizumab for Plaque and Guttate Psoriasis in a Patient With IgA-Related Glomerulonephritis
por: Annunziata Dattola, et al.
Publicado: (2021)

Current knowledge on psoriasis and autoimmune diseases
por: Ayala-Fontánez N, et al.
Publicado: (2016)

Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic
por: Haulrig MB, et al.
Publicado: (2021)

Diagnosis and screening of patients with generalized pustular psoriasis
por: Ly K, et al.
Publicado: (2019)

Psoriasis and Cardiometabolic Diseases: The Impact of Inflammation on Vascular Health
por: Teklu M, et al.
Publicado: (2021)

Single-center, noninterventional clinical trial to assess the safety, efficacy, and tolerability of a dimeticone-based medical device in facilitating the removal of scales after topical application in patients with psoriasis corporis or psoriasis capitis
por: Hengge UR, et al.
Publicado: (2017)

Serum TSLP is a potential biomarker of psoriasis vulgaris activity
por: El-Ghareeb MI, et al.
Publicado: (2019)

Assessment and monitoring of biologic drug adverse events in patients with psoriasis
por: Hanley T, et al.
Publicado: (2016)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
por: Riccardo G. Borroni, et al.
Publicado: (2021)

An Atypical Case of Pustular Psoriasis Presenting With Severe Subungual Abscesses Involving All Fingers
por: A. Tulin Mansur
Publicado: (2019)

Erythrodermic psoriasis: pathophysiology and current treatment perspectives
por: Singh RK, et al.
Publicado: (2016)

Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives
por: Campanati A, et al.
Publicado: (2017)

Prevalence of Metabolic Syndrome and Its Parameters and Their Correlations With Psoriasis Duration, Severity, and Sleep Quality In Psoriasis Patients: A Cross-Sectional Study
por: Betul Tas, et al.
Publicado: (2021)

The new external drug for the treatment of psoriasis based on inhibition of serine proteases
por: Alexander S. Zhukov, et al.
Publicado: (2021)

Tacrolimus for the management of psoriasis: clinical utility and place in therapy
por: Malecic N, et al.
Publicado: (2016)

Psoriasis and sexual dysfunction: links, risks, and management challenges
por: Duarte GV, et al.
Publicado: (2018)

Clinical evidence of therapy for genital psoriasis by biologic agents
por: Evgeny V. Sokolovskiy, et al.
Publicado: (2021)

Phosphodiesterase-4 Inhibition in Psoriasis
por: Milakovic M, et al.
Publicado: (2021)

Pubic Lice In Facial Hair
por: Puravoor Jayasree, et al.
Publicado: (2020)

The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan M, et al.
Publicado: (2021)

Psoriasis In Patients With Active Lung Cancer: Is Apremilast a Safe Option?
por: Zoe Apalla, et al.
Publicado: (2019)

Dermoscopy Differentiates Guttate Psoriasis From a Mimicker—Pityriasis Rosea
por: Meena Makhecha, et al.
Publicado: (2021)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Aline Lissa Okita, et al.
Publicado: (2020)

Psoriasis patients’ experiences concerning medical adherence to treatment with topical corticosteroids
por: Svendsen MT, et al.
Publicado: (2016)

Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal microscopy
por: Agozzino M, et al.
Publicado: (2017)

Type 2 diabetes and psoriasis: links and risks
por: Holm JG, et al.
Publicado: (2019)

Association of HLA Alleles and HLA Haplotypes with Psoriasis, Psoriatic Arthritis and Disease Severity in a Miscegenated Population
por: Cassia FF, et al.
Publicado: (2021)

Excimer laser for the treatment of psoriasis: safety, efficacy, and patient acceptability
por: Abrouk M, et al.
Publicado: (2016)

Nd:YAG Laser in the Treatment of Nail Psoriasis: Clinical and Dermoscopic Assessment
por: Yasmin Hesham Ali Elwan, et al.
Publicado: (2021)